Table of Contents Chapter 1 Overview of Systemic Idiopathic Juvenile Arthritis Treatment 1.1 Definition of Systemic Idiopathic Juvenile Arthritis Treatment in This Report 1.2 Commercial Types of Systemic Idiopathic Juvenile Arthritis Treatment 1.2.1 Adalimumab Biosimilar 1.2.2 Canakinumab 1.2.3 Golimumab 1.2.4 Tocilizumab Biosimilar 1.2.5 Others 1.3 Downstream Application of Systemic Idiopathic Juvenile Arthritis Treatment 1.3.1 Clinic 1.3.2 Hospital 1.3.3 Others 1.4 Development History of Systemic Idiopathic Juvenile Arthritis Treatment 1.5 Market Status and Trend of Systemic Idiopathic Juvenile Arthritis Treatment 2013-2023 1.5.1 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Status and Trend 2013-2023 1.5.2 Regional Systemic Idiopathic Juvenile Arthritis Treatment Market Status and Trend 2013-2023 Chapter 2 Global Market Status and Forecast by Regions 2.1 Market Development of Systemic Idiopathic Juvenile Arthritis Treatment 2013-2017 2.2 Sales Market of Systemic Idiopathic Juvenile Arthritis Treatment by Regions 2.2.1 Sales Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Regions 2.2.2 Sales Value of Systemic Idiopathic Juvenile Arthritis Treatment by Regions 2.3 Production Market of Systemic Idiopathic Juvenile Arthritis Treatment by Regions 2.4 Global Market Forecast of Systemic Idiopathic Juvenile Arthritis Treatment 2018-2023 2.4.1 Global Market Forecast of Systemic Idiopathic Juvenile Arthritis Treatment 2018-2023 2.4.2 Market Forecast of Systemic Idiopathic Juvenile Arthritis Treatment by Regions 2018-2023 Chapter 3 Global Market Status and Forecast by Types 3.1 Sales Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Types 3.2 Sales Value of Systemic Idiopathic Juvenile Arthritis Treatment by Types 3.3 Market Forecast of Systemic Idiopathic Juvenile Arthritis Treatment by Types Chapter 4 Global Market Status and Forecast by Downstream Industry 4.1 Global Sales Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Downstream Industry 4.2 Global Market Forecast of Systemic Idiopathic Juvenile Arthritis Treatment by Downstream Industry Chapter 5 North America Market Status by Countries, Type, Manufacturers and Downstream Industry 5.1 North America Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Countries 5.1.1 North America Systemic Idiopathic Juvenile Arthritis Treatment Sales by Countries (2013-2017) 5.1.2 North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Countries (2013-2017) 5.1.3 United States Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 5.1.4 Canada Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 5.1.5 Mexico Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 5.2 North America Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Manufacturers 5.3 North America Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Type (2013-2017) 5.3.1 North America Systemic Idiopathic Juvenile Arthritis Treatment Sales by Type (2013-2017) 5.3.2 North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2013-2017) 5.4 North America Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Downstream Industry (2013-2017) Chapter 6 Europe Market Status by Countries, Type, Manufacturers and Downstream Industry 6.1 Europe Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Countries 6.1.1 Europe Systemic Idiopathic Juvenile Arthritis Treatment Sales by Countries (2013-2017) 6.1.2 Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Countries (2013-2017) 6.1.3 Germany Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 6.1.4 UK Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 6.1.5 France Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 6.1.6 Italy Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 6.1.7 Russia Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 6.1.8 Spain Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 6.1.9 Benelux Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 6.2 Europe Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Manufacturers 6.3 Europe Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Type (2013-2017) 6.3.1 Europe Systemic Idiopathic Juvenile Arthritis Treatment Sales by Type (2013-2017) 6.3.2 Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2013-2017) 6.4 Europe Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Downstream Industry (2013-2017) Chapter 7 Asia Pacific Market Status by Countries, Type, Manufacturers and Downstream Industry 7.1 Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Countries 7.1.1 Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Sales by Countries (2013-2017) 7.1.2 Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Countries (2013-2017) 7.1.3 China Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 7.1.4 Japan Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 7.1.5 India Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 7.1.6 Southeast Asia Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 7.1.7 Australia Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 7.2 Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Manufacturers 7.3 Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Type (2013-2017) 7.3.1 Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Sales by Type (2013-2017) 7.3.2 Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2013-2017) 7.4 Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Downstream Industry (2013-2017) Chapter 8 Latin America Market Status by Countries, Type, Manufacturers and Downstream Industry 8.1 Latin America Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Countries 8.1.1 Latin America Systemic Idiopathic Juvenile Arthritis Treatment Sales by Countries (2013-2017) 8.1.2 Latin America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Countries (2013-2017) 8.1.3 Brazil Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 8.1.4 Argentina Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 8.1.5 Colombia Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 8.2 Latin America Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Manufacturers 8.3 Latin America Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Type (2013-2017) 8.3.1 Latin America Systemic Idiopathic Juvenile Arthritis Treatment Sales by Type (2013-2017) 8.3.2 Latin America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2013-2017) 8.4 Latin America Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Downstream Industry (2013-2017) Chapter 9 Middle East and Africa Market Status by Countries, Type, Manufacturers and Downstream Industry 9.1 Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Countries 9.1.1 Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Sales by Countries (2013-2017) 9.1.2 Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Countries (2013-2017) 9.1.3 Middle East Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 9.1.4 Africa Systemic Idiopathic Juvenile Arthritis Treatment Market Status (2013-2017) 9.2 Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Manufacturers 9.3 Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Type (2013-2017) 9.3.1 Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Sales by Type (2013-2017) 9.3.2 Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2013-2017) 9.4 Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Market Status by Downstream Industry (2013-2017) Chapter 10 Market Driving Factor Analysis of Systemic Idiopathic Juvenile Arthritis Treatment 10.1 Global Economy Situation and Trend Overview 10.2 Systemic Idiopathic Juvenile Arthritis Treatment Downstream Industry Situation and Trend Overview Chapter 11 Systemic Idiopathic Juvenile Arthritis Treatment Market Competition Status by Major Manufacturers 11.1 Production Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Major Manufacturers 11.2 Production Value of Systemic Idiopathic Juvenile Arthritis Treatment by Major Manufacturers 11.3 Basic Information of Systemic Idiopathic Juvenile Arthritis Treatment by Major Manufacturers 11.3.1 Headquarters Location and Established Time of Systemic Idiopathic Juvenile Arthritis Treatment Major Manufacturer 11.3.2 Employees and Revenue Level of Systemic Idiopathic Juvenile Arthritis Treatment Major Manufacturer 11.4 Market Competition News and Trend 11.4.1 Merger, Consolidation or Acquisition News 11.4.2 Investment or Disinvestment News 11.4.3 New Product Development and Launch Chapter 12 Systemic Idiopathic Juvenile Arthritis Treatment Major Manufacturers Introduction and Market Data 12.1 Alteogen Inc. 12.1.1 Company profile 12.1.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product 12.1.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Alteogen Inc. 12.2 Bristol-Myers Squibb Company 12.2.1 Company profile 12.2.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product 12.2.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company 12.3 Epirus Biopharmaceuticals, Inc. 12.3.1 Company profile 12.3.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product 12.3.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Epirus Biopharmaceuticals, Inc. 12.4 Johnson & Johnson 12.4.1 Company profile 12.4.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product 12.4.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Johnson & Johnson 12.5 Momenta Pharmaceuticals, Inc. 12.5.1 Company profile 12.5.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product 12.5.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Momenta Pharmaceuticals, Inc. 12.6 Mycenax Biotech Inc. 12.6.1 Company profile 12.6.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product 12.6.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Mycenax Biotech Inc. 12.7 Novartis AG 12.7.1 Company profile 12.7.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product 12.7.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Novartis AG 12.8 Oncobiologics, Inc. 12.8.1 Company profile 12.8.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product 12.8.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Oncobiologics, Inc. Chapter 13 Upstream and Downstream Market Analysis of Systemic Idiopathic Juvenile Arthritis Treatment 13.1 Industry Chain of Systemic Idiopathic Juvenile Arthritis Treatment 13.2 Upstream Market and Representative Companies Analysis 13.3 Downstream Market and Representative Companies Analysis Chapter 14 Cost and Gross Margin Analysis of Systemic Idiopathic Juvenile Arthritis Treatment 14.1 Cost Structure Analysis of Systemic Idiopathic Juvenile Arthritis Treatment 14.2 Raw Materials Cost Analysis of Systemic Idiopathic Juvenile Arthritis Treatment 14.3 Labor Cost Analysis of Systemic Idiopathic Juvenile Arthritis Treatment 14.4 Manufacturing Expenses Analysis of Systemic Idiopathic Juvenile Arthritis Treatment Chapter 15 Report Conclusion Chapter 16 Research Methodology and Reference 16.1 Methodology/Research Approach 16.1.1 Research Programs/Design 16.1.2 Market Size Estimation 16.1.3 Market Breakdown and Data Triangulation 16.2 Data Source 16.2.1 Secondary Sources 16.2.2 Primary Sources 16.3 Reference

List of Tables Table Advantage and Disadvantage of Adalimumab Biosimilar Table Advantage and Disadvantage of Canakinumab Table Advantage and Disadvantage of Golimumab Table Advantage and Disadvantage of Tocilizumab Biosimilar Table Advantage and Disadvantage of Others Table Sales Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Regions 2013-2017 Table Sales Value of Systemic Idiopathic Juvenile Arthritis Treatment by Regions 2013-2017 Table Production Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Regions 2013-2017 Table Global Sales Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Regions 2018-2023 Table Global Sales Value of Systemic Idiopathic Juvenile Arthritis Treatment by Regions 2018-2023 Table Global Production Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Regions 2018-2023 Table Sales Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Types 2013-2017 Table Sales Value of Systemic Idiopathic Juvenile Arthritis Treatment by Types 2013-2017 Table Sales Volume Forecast of Systemic Idiopathic Juvenile Arthritis Treatment by Types 2018-2023 Table Sales Value Forecast of Systemic Idiopathic Juvenile Arthritis Treatment by Types 2018-2023 Table Sales Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Downstream Industry 2013-2017 Table Sales Volume Forecast of Systemic Idiopathic Juvenile Arthritis Treatment by Downstream Industry 2018-2023 Table North America Systemic Idiopathic Juvenile Arthritis Treatment Sales by Countries (2013-2017) Table North America Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Countries (2013-2017) Table North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Countries (2013-2017) Table North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Countries (2013-2017) Table North America Systemic Idiopathic Juvenile Arthritis Treatment Sales by Type (2013-2017) Table North America Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Type (2013-2017) Table North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2013-2017) Table North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue Share by Type (2013-2017) Table North America Systemic Idiopathic Juvenile Arthritis Treatment Sales by Downstream Industry (2013-2017) Table North America Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Downstream Industry (2013-2017) Table Europe Systemic Idiopathic Juvenile Arthritis Treatment Sales by Countries (2013-2017) Table Europe Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Countries (2013-2017) Table Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Countries (2013-2017) Table Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Countries (2013-2017) Table Europe Systemic Idiopathic Juvenile Arthritis Treatment Sales by Type (2013-2017) Table Europe Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Type (2013-2017) Table Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2013-2017) Table Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue Share by Type (2013-2017) Table Europe Systemic Idiopathic Juvenile Arthritis Treatment Sales by Downstream Industry (2013-2017) Table Europe Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Downstream Industry (2013-2017) Table Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Sales by Countries (2013-2017) Table Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Countries (2013-2017) Table Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Countries (2013-2017) Table Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Countries (2013-2017) Table Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Sales by Type (2013-2017) Table Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Type (2013-2017) Table Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2013-2017) Table Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue Share by Type (2013-2017) Table Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Sales by Downstream Industry (2013-2017) Table Asia Pacific Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Downstream Industry (2013-2017) Table Latin America Systemic Idiopathic Juvenile Arthritis Treatment Sales by Countries (2013-2017) Table Latin America Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Countries (2013-2017) Table Latin America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Countries (2013-2017) Table Latin America Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Countries (2013-2017) Table Latin America Systemic Idiopathic Juvenile Arthritis Treatment Sales by Type (2013-2017) Table Latin America Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Type (2013-2017) Table Latin America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2013-2017) Table Latin America Systemic Idiopathic Juvenile Arthritis Treatment Revenue Share by Type (2013-2017) Table Latin America Systemic Idiopathic Juvenile Arthritis Treatment Sales by Downstream Industry (2013-2017) Table Latin America Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Downstream Industry (2013-2017) Table Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Sales by Regions (2013-2017) Table Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Regions (2013-2017) Table Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Regions (2013-2017) Table Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Regions (2013-2017) Table Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Sales by Type (2013-2017) Table Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Type (2013-2017) Table Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2013-2017) Table Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue Share by Type (2013-2017) Table Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Sales by Downstream Industry (2013-2017) Table Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Sales Share by Downstream Industry (2013-2017) Table Production Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Major Manufacturers 2013-2017 Table Production Value of Systemic Idiopathic Juvenile Arthritis Treatment by Major Manufacturers 2013-2017 Table Headquarters Location and Established Time of Systemic Idiopathic Juvenile Arthritis Treatment Major Manufacturer Table Employees and Revenue Level of Systemic Idiopathic Juvenile Arthritis Treatment Major Manufacturer Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product One of Alteogen Inc. Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product Two of Alteogen Inc. Table Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Alteogen Inc. 2013-2017 Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product One of Bristol-Myers Squibb Company Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product Two of Bristol-Myers Squibb Company Table Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company 2013-2017 Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product One of Epirus Biopharmaceuticals, Inc. Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product Two of Epirus Biopharmaceuticals, Inc. Table Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Epirus Biopharmaceuticals, Inc. 2013-2017 Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product One of Johnson & Johnson Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product Two of Johnson & Johnson Table Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Johnson & Johnson 2013-2017 Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product One of Momenta Pharmaceuticals, Inc. Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product Two of Momenta Pharmaceuticals, Inc. Table Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Momenta Pharmaceuticals, Inc. 2013-2017 Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product One of Mycenax Biotech Inc. Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product Two of Mycenax Biotech Inc. Table Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Mycenax Biotech Inc. 2013-2017 Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product One of Novartis AG Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product Two of Novartis AG Table Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Novartis AG 2013-2017 Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product One of Oncobiologics, Inc. Table Representative Systemic Idiopathic Juvenile Arthritis Treatment Product Two of Oncobiologics, Inc. Table Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Oncobiologics, Inc. 2013-2017